Phase III double-blind clinical trials started in March 2008 with the IDENTITY study (Interrupting Alzheimer's dementia by evaluating treatment of amyloid pathology), including 1500 patients from 22 countries. This study was intended to run until May 2011. The successor trial with further 1500 patients, IDENTITY-2, started in September 2008. The open-label trial IDENTITY-XT, which included patients who have completed one of the two studies, started in December 2009. On 17 August 2010, it was announced that the phase III trials failed. Preliminary findings show that not only did<unk>  fail to slow disease progression, but that it was actually associated with “worsening of clinical measures of cognition and the ability to perform activities of daily living”. Furthermore, the incidence of skin cancer was significantly higher in the treatment group than the placebo group.
Semagacestat
Dienogest
Gestonorone caproate
Triptorelin
Lumacaftor
Migalastat
Olestra
Ingenol mebutate